Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 26.76M P/E - EPS this Y -3.70% Ern Qtrly Grth -
Income -17.93M Forward P/E -1.09 EPS next Y -13.90% 50D Avg Chg 6.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 9.00%
Dividend N/A Price/Book 0.62 EPS next 5Y - 52W High Chg -58.00%
Recommedations 2.00 Quick Ratio 7.24 Shares Outstanding 10.17M 52W Low Chg 51.00%
Insider Own 30.03% ROA -46.06% Shares Float 7.11M Beta 1.42
Inst Own 6.67% ROE -68.86% Shares Shorted/Prior 67.06K/57.30K Price 2.63
Gross Margin - Profit Margin - Avg. Volume 26,996 Target Price 8.00
Oper. Margin - Earnings Date Nov 11 Volume 14,390 Change 2.33%
About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Cocrystal Pharma, Inc. News
12/17/24 US Penny Stocks To Watch In December 2024
11/19/24 COCP: Multiple Upcoming Catalysts…
11/14/24 November 2024 US Exchange Standouts: Promising Penny Stocks
11/13/24 Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
10/31/24 Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
10/18/24 Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation
09/26/24 Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
08/19/24 Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
08/19/24 COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…
08/15/24 CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
08/14/24 Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
07/19/24 COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…
07/18/24 Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
07/02/24 COCP: CC-42344 Shows In Vitro Activity Against Avian Influenza A (H5N1)…
06/20/24 New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
06/07/24 Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
05/16/24 COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344…
05/13/24 Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
05/01/24 Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
04/23/24 COCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…